Family medicine clinicians managing GLP-1 therapy should understand that direct-to-consumer telehealth platforms like Hers are actively capturing patients who might otherwise present to primary care, meaning clinicians will increasingly encounter patients who are already self-initiating GLP-1 therapy without baseline metabolic workup, contraindication screening, or structured follow-up. This creates real clinical risk, particularly around undetected thyroid pathology, pancreatitis history, or concurrent medications that require monitoring. Awareness of these platforms also helps clinicians have informed conversations with patients about care coordination, appropriate laboratory surveillance, and the limitations of prescribing models that lack longitudinal physician-patient relationships.
The source material provided is a consumer-facing news article from the New York Post describing the telehealth platform Hers and its service offerings, including GLP-1 weight loss programs, hair loss treatments, and mental health services. This is not a clinical study, trial, or peer-reviewed publication. There are no research methods, patient populations, outcome measures, or quantitative findings to summarize.
A clinical summary cannot be produced from this content because no data were studied and no findings were reported. To generate a physician-level clinical summary of the type requested, please provide a peer-reviewed publication, clinical trial report, or structured observational study with reportable outcomes and methodology.
Hers is a telehealth platform offering women access to GLP-1 medications for weight loss, alongside services for hair loss and mental health, often without the traditional in-office visit. The convenience and lower perceived cost barrier are driving significant consumer interest, but patients may not fully understand the clinical oversight differences between telehealth prescribing and longitudinal primary care management. GLP-1 therapy requires ongoing monitoring of metabolic markers, gastrointestinal tolerance, and dosing adjustments that are best coordinated with a clinician who knows the patient’s full medical history. Family medicine providers should proactively ask patients if they are using or considering direct-to-consumer telehealth platforms for GLP-1s, as this opens the door to safety conversations about compounded medications, appropriate candidacy screening, and the importance of integrated follow-up care.
“The rise of platforms like Hers reflects something I see playing out in my own practice every day: patients, particularly women, are exhausted by a healthcare system that has historically minimized their concerns around weight, hormones, and mental health. Telehealth models that expand access to GLP-1 therapy are not inherently the problem, but the absence of longitudinal monitoring, metabolic baseline assessment, and individualized dose titration absolutely is. When I talk with patients who come to me after starting a GLP-1 through a direct-to-consumer platform, the most common gap I find is that no one ever explained to them what to watch for, what to report, or how to adjust when side effects emerge. The clinical implication here is clear: access without ongoing guidance is not care, and patients deserve a provider who will stay in the conversation with them well beyond the prescription.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- What is a GLP-1 medication?
- How do GLP-1 medications help with weight loss?
- Are GLP-1 medications safe for long-term use?
- What are the most common side effects of GLP-1 therapy?
- Can I get GLP-1 medications through telehealth platforms like Hers?
- Is a telehealth prescription for a GLP-1 as safe as getting one from my regular doctor?
- How much do GLP-1 medications typically cost?
- Who is a good candidate for GLP-1 therapy?
- Will I need to stay on a GLP-1 medication forever?
- Can GLP-1 medications affect mental health or mood?
FAQ
What is a GLP-1 medication?
GLP-1 medications are a class of drugs that mimic a hormone your body naturally produces to regulate blood sugar and appetite. They work by slowing digestion, reducing hunger signals in the brain, and helping the body release insulin more appropriately. Semaglutide and tirzepatide are among the most well-known examples currently available.
How do GLP-1 medications help with weight loss?
These medications reduce appetite and slow the rate at which food leaves your stomach, which helps most people eat less without feeling deprived. Clinical trials have shown average weight loss ranging from 10 to 22 percent of total body weight depending on the specific medication and dose. The effect is strongest when combined with changes in diet and physical activity.
Are GLP-1 medications safe for long-term use?
The safety profile of GLP-1 medications has been studied extensively in large clinical trials lasting several years. Serious side effects are uncommon, and the cardiovascular benefits are well documented in people with obesity and type 2 diabetes. Your physician should monitor you regularly to assess how your body is responding over time.
What are the most common side effects of GLP-1 therapy?
Nausea, vomiting, constipation, and diarrhea are the most frequently reported side effects, particularly when starting treatment or increasing the dose. These symptoms are usually temporary and tend to improve as your body adjusts to the medication. Dosing is typically increased gradually to minimize discomfort.
Can I get GLP-1 medications through telehealth platforms like Hers?
Some telehealth platforms do prescribe GLP-1 medications after a remote consultation with a licensed clinician. The quality of care can vary significantly depending on the platform, the prescribing standards used, and the level of ongoing medical supervision provided. It is important to ensure that whoever prescribes your medication is conducting a thorough evaluation of your health history.
Is a telehealth prescription for a GLP-1 as safe as getting one from my regular doctor?
Safety depends less on the platform and more on the thoroughness of the clinical evaluation and the quality of follow-up care provided. A responsible prescriber, whether in person or remote, will review your full medical history, screen for contraindications, and monitor you throughout treatment. Patients should be cautious of platforms that prioritize speed over clinical rigor.
How much do GLP-1 medications typically cost?
Brand-name GLP-1 medications like Ozempic and Wegovy can cost between 900 and 1,400 dollars per month without insurance coverage. Compounded versions available through some telehealth providers are often less expensive but carry their own regulatory and quality considerations. Insurance coverage varies widely and is often easier to obtain with a documented diagnosis of type 2 diabetes or obesity-related conditions.
Who is a good candidate for GLP-1 therapy?
GLP-1 medications are generally appropriate for adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related health condition such as high blood pressure, high cholesterol, or type 2 diabetes. A full medical evaluation is necessary to confirm there are no contraindications such as a personal or family history of medullary thyroid cancer. The decision should always be individualized based on your complete health picture.
Will I need to stay on a GLP-1 medication forever?
Research shows that most people regain a significant portion of lost weight after stopping GLP-1 therapy, which suggests the medication is treating an ongoing biological condition rather than providing a one-time fix. Whether to continue long term is a clinical decision that depends on your health goals, tolerance of the medication, and response to treatment. Your physician can help you weigh the benefits and risks of continued use over time.
Can GLP-1 medications affect mental health or mood?
Some patients report improvements in mood, reduced food preoccupation, and better overall quality of life during GLP-1 therapy, which may be related to the medication’s effects on brain reward pathways. There have also been reports of depressive symptoms and, rarely, suicidal ideation, which the FDA is actively monitoring. You should inform your prescribing clinician promptly if you notice any changes in your mood or mental health after starting treatment.
